ASCO 2013:醋用新方,成功检测子宫颈癌

2013-06-05 佚名 生物360

研究人员对 15 万名印度妇女所做的调查发现,一种用醋和目测的简易检查方式能够使子宫颈癌的死亡率减少 31%。 印度研究人员周日(6月2日)在美国临床肿瘤协会在芝加哥召开的会议上表示,如果这种新型检查方式广泛实施,那么每年可以在印度减少 22,000 个宫颈癌死亡病例,每年在发展中国家减少 72,000 个死亡病例。 醋检法非常简单易用,子宫颈如果有癌前病变,涂抹醋一分钟后,癌前病变组织将呈白

研究人员对 15 万名印度妇女所做的调查发现,一种用醋和目测的简易检查方式能够使子宫颈癌的死亡率减少 31%。

印度研究人员周日(6月2日)在美国临床肿瘤协会在芝加哥召开的会议上表示,如果这种新型检查方式广泛实施,那么每年可以在印度减少 22,000 个宫颈癌死亡病例,每年在发展中国家减少 72,000 个死亡病例。

醋检法非常简单易用,子宫颈如果有癌前病变,涂抹醋一分钟后,癌前病变组织将呈白色,肉眼就可以辨认。

主导这项研究的印度孟买塔塔纪念医院的沙斯特里医生在会上说,针对 15 万印度贫困妇女的调查显示,该简易检查方式使这一人群的宫颈癌死亡率减少了 31%,“意义非常重大”。

宫颈癌是印度妇女以及很多发展中国家妇女的高发杀手。

沙斯特里医生表示,印度目前没有宫颈癌检查项目,主要因为没有发达国家最常见的抹片检查所涉及的基础设施、高成本等。

这一研究项目以印度孟买 20 处贫民窟生活的 35 至 64 岁且没有癌症病史的妇女为研究对象。为了克服社会障碍,研究小组事先与当地宗教、政治以及社区方面会面,争取支持。

研究小组培训至少有 10 年级教育背景的青年女性如何在检查中应用醋液并评估结果。

美国科罗拉多大学癌症研究中心的斯比尔曼医生表示,在非洲也展开了类似的检查项目。

Landmark Studies Offer New Hope for Reducing Cervical Cancer Deaths
Five pivotal studies were released today ahead of the plenary session of the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO). Abstracts selected for the ASCO’s plenary session represent the meeting’s most important clinical cancer research, having the highest scientific merit and the greatest impact on oncology research and practice.
“Today’s results show that progress can happen at both ends of the technology spectrum, from cutting-edge drugs to the simple use of vinegar to detect cervical cancer,” said moderator and ASCO spokesperson Jyoti Patel, MD, an oncologist at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, Ill. “It is especially gratifying that some of this meeting’s biggest advances are against cervical cancer, which affects the most disadvantaged women in every society. At the same time, patients with thyroid, breast and brain cancers will live better, and in some cases longer, due to studies presented today...

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938227, encodeId=6800193822ecd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jul 21 21:33:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006680, encodeId=fda7200668061, content=<a href='/topic/show?id=199d452095f' target=_blank style='color:#2F92EE;'>#子宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45209, encryptionId=199d452095f, topicName=子宫颈)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 01 22:33:00 CST 2013, time=2013-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282856, encodeId=1b3312828561b, content=<a href='/topic/show?id=53f24521227' target=_blank style='color:#2F92EE;'>#子宫颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45212, encryptionId=53f24521227, topicName=子宫颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6411176, createdName=mfx799, createdTime=Fri Jun 07 00:33:00 CST 2013, time=2013-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407902, encodeId=03f1140e902bb, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jun 07 00:33:00 CST 2013, time=2013-06-07, status=1, ipAttribution=)]
    2013-07-21 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1938227, encodeId=6800193822ecd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jul 21 21:33:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006680, encodeId=fda7200668061, content=<a href='/topic/show?id=199d452095f' target=_blank style='color:#2F92EE;'>#子宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45209, encryptionId=199d452095f, topicName=子宫颈)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 01 22:33:00 CST 2013, time=2013-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282856, encodeId=1b3312828561b, content=<a href='/topic/show?id=53f24521227' target=_blank style='color:#2F92EE;'>#子宫颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45212, encryptionId=53f24521227, topicName=子宫颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6411176, createdName=mfx799, createdTime=Fri Jun 07 00:33:00 CST 2013, time=2013-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407902, encodeId=03f1140e902bb, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jun 07 00:33:00 CST 2013, time=2013-06-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1938227, encodeId=6800193822ecd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jul 21 21:33:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006680, encodeId=fda7200668061, content=<a href='/topic/show?id=199d452095f' target=_blank style='color:#2F92EE;'>#子宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45209, encryptionId=199d452095f, topicName=子宫颈)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 01 22:33:00 CST 2013, time=2013-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282856, encodeId=1b3312828561b, content=<a href='/topic/show?id=53f24521227' target=_blank style='color:#2F92EE;'>#子宫颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45212, encryptionId=53f24521227, topicName=子宫颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6411176, createdName=mfx799, createdTime=Fri Jun 07 00:33:00 CST 2013, time=2013-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407902, encodeId=03f1140e902bb, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jun 07 00:33:00 CST 2013, time=2013-06-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1938227, encodeId=6800193822ecd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Jul 21 21:33:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006680, encodeId=fda7200668061, content=<a href='/topic/show?id=199d452095f' target=_blank style='color:#2F92EE;'>#子宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45209, encryptionId=199d452095f, topicName=子宫颈)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sun Sep 01 22:33:00 CST 2013, time=2013-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282856, encodeId=1b3312828561b, content=<a href='/topic/show?id=53f24521227' target=_blank style='color:#2F92EE;'>#子宫颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45212, encryptionId=53f24521227, topicName=子宫颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6411176, createdName=mfx799, createdTime=Fri Jun 07 00:33:00 CST 2013, time=2013-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407902, encodeId=03f1140e902bb, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jun 07 00:33:00 CST 2013, time=2013-06-07, status=1, ipAttribution=)]
    2013-06-07 一闲

相关资讯

ASCO 2013:上海胸科医院顾爱琴等证实埃克替尼对晚期非小细胞肺癌患者治疗安全有效

在中国国家食品药品监督管理局批准了埃克替尼在临床的应用之后,研究者进行了ICOGEN的III期临床研究,该研究证实在对患者的无进展生存期改善方面,埃克替尼的疗效不劣于吉非替尼。在本研究中,研究者所进行的是安全监督研究以评价在中国晚期非小细胞肺癌患者中,应用埃克替尼的有效性和安全性情况。本研究为单组、开放式标签、多中心研究,研究主要针对晚期非小细胞肺癌患者,并且这些患者可接受每日三次,每次口服125

ASCO 2013:香港中文大学莫树锦等证实pEGFR mut能有效预测非小细胞肺癌患者的预后

在FASTACT 2中,研究者对肿瘤生物标记物的分析证实了在晚期非小细胞肺癌患者中,EGFR突变有助于预测厄洛替尼联合化疗作为一线治疗对上述患者所带来的治疗获益。然而,在该研究中的肿瘤标本有限。最近技术的发展能够促使从不含细胞的血浆DNA中检测到EGFR突变状态(pEGFRmut)。在本研究中,研究者们旨在评估pEGFRmut和来自肿瘤组织的EGFR mut之间是否存在一定关联,同时也评估pEGF

JCO:ASCO新指南肯定癌症患者保存卵母细胞

  根据美国临床肿瘤学会(ASCO)发布的新版新诊断癌症患者保存生育力指南,保存卵母细胞已不再只是一种经验性选择,而是成为了一种标准措施。   不过除了肯定保存卵母细胞的做法之外,新版指南提出的建议与2006年版指南几乎完全一致。新版指南还纳入了新的文献,以便为医患之间关于保存生育力问题的讨论搭建框架。这部指南发表在《临床肿瘤杂志》5月28日在线版上Fertility Preservation

ASCO 2013:双联免疫治疗转移性黑色素瘤

  纽约纪念Sloan-Kettering癌症中心的Jedd D. Wolchok博士在美国临床肿瘤学会(ASCO)2013年会前的新闻发布会上宣布,对转移性黑色素瘤患者联合使用作用机制不同的两种免疫治疗药物,已在早期研究中取得了初步成功。   在纳入37例患者的Ⅰ期研究中,伊匹单抗(Yervoy)联合在研药物nivolumab使Ⅲ~Ⅳ期黑色素瘤缩小了大约一半。治疗12周时,

ASCO 2013:影像学无益于诊断侵袭性淋巴瘤复发

  梅奥诊所的一项研究发现,弥漫性大B细胞性淋巴瘤治疗后行影像学扫描无助于检测复发。研究者说,绝大多数罹患此侵袭性淋巴瘤的患者在复发时已有症状,他们的体格检查或血液检查结果异常。该发现将于3月31日-6月4日在芝加哥的美国临床肿瘤学会的年度会议上公布。   “我们的结果令人惊讶,因为目前的该疾病的护理标准包括随访时扫描,”第一作者Carrie Thompson(医学博士,梅奥诊所血液病学家)说。